Artrya’s AI Heart Scan Breakthrough: FDA Clears Path for US Expansion

Artrya Limited’s Salix® AI platform, now FDA-cleared, revolutionizes coronary artery disease diagnosis with rapid, non-invasive heart scans. Cutting costs and time, it empowers US hospitals and patients with precise, real-time results. Backed by $15M and Australian partnerships, Artrya’s market-based innovation tackles a global health crisis. Our analysis dives into its tech, impact, and why private-sector solutions outpace government-led alternatives. Watch to explore how AI is reshaping healthcare! 🩺💡 Like & subscribe to InsightBit for cutting-edge health insights! #Artrya #Salix #AIHealthcare #CoronaryArteryDisease #FDAClearance #HealthTech #MedicalInnovation #HeartHealth #PrivateSector #HealthcareSolutions #AIdiagnostics #Cardiology #HealthPolicy #MarketBasedCare #InsightBit